Maintenance Bavencio with Inlyta interruption is feasible in mRCC, showing promising PFS and OS rates at 31.7 months follow-up. Patients interrupting Inlyta at week 36 had a 24-month PFS rate of 58% ...
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma. Ensuring treatment adherence while minimizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results